Heron Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

• Heron Therapeutics Inc HRTX.OQ reported quarterly adjusted earnings of 2 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -7 cents. The mean expectation of three analysts for the quarter was for a loss of 3 cents per share. Wall Street expected results to range from -3 cents to -2 cents per share.

• Revenue rose 19.1% to $40.78 million from a year ago; analysts expected $37.37 million.

• Heron Therapeutics Inc's reported EPS for the quarter was 2 cents​.

• The company reported quarterly net income of $3.66 million.

• Heron Therapeutics Inc shares had risen by 11.8% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts was unchanged in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Heron Therapeutics Inc is $5.00

This summary was machine generated from LSEG data February 27 at 03:59 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)